首页 | 本学科首页   官方微博 | 高级检索  
     


Phase II Study of UFT in Patients With Advanced Non-Small Cell Lung Cancer
Authors:KEICHO, NAOTO   SAIJO, NAGAHIRO   SHINKAI, TETSU   EGUCHI, KENJI   SASAKI, YASUTSUNA   TAMURA, TOMOHIDE   SAKURAI, MASANORI   SANO, TETSURO   HOSHI, AKIO
Affiliation:Department of Internal Medicine, National Cancer Center Hospital Tokyo
*Pharmacology Division, National Cancer Center Research Institute Tokyo
Abstract:A phase II study of UFT (a mixture of uracil and tegafur; molarratio of uracil to tegafur = 4) was undertaken in 21 patientswith advanced non-small cell lung cancer (NSCLC). UFT was administeredorally at a dose of 400 mg/m2 every day, for more than fourweeks. Of 16 adequately treated patients, one (6.3%) showed a partialresponse. Toxic effects included minimal myelosuppression, anorexia,nausea, vomiting and epigastralgia. Gastrointestinal toxicitywas well tolerated. Considering the poor response and mild toxicity,a further phase II study of higher-dose UFT is necessary forpatients without prior therapy.
Keywords:
本文献已被 Oxford 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号